CD274 and nasopharyngeal carcinoma: Among 44 unselected advanced patients with NPC treated with nivolumab, the ORR was 20.5%.10 In KEYNOTE-028 study, 19 patients with PD-L1+ NPC treated with pembrolizumab had an ORR of 26.3%.11 Among 91 unselected advanced patients with NPC treated with camrelizumab, the ORR was 34.1%.12